^
    2ms
    Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically (clinicaltrials.gov)
    P=N/A, N=125, Not yet recruiting, Dartmouth-Hitchcock Medical Center
    New trial
    |
    Ameluz (aminolevulinic acid)
    6ms
    Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses (clinicaltrials.gov)
    P2, N=30, Completed, Case Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jul 2024
    Trial completion • Trial completion date
    |
    Ameluz (aminolevulinic acid)
    7ms
    Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults (clinicaltrials.gov)
    P2, N=126, Active, not recruiting, Biofrontera Bioscience GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Ameluz (aminolevulinic acid)
    9ms
    Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp (clinicaltrials.gov)
    P3, N=172, Active, not recruiting, Biofrontera Bioscience GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Ameluz (aminolevulinic acid)
    10ms
    Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults (clinicaltrials.gov)
    P2, N=126, Recruiting, Biofrontera Bioscience GmbH | Trial completion date: Feb 2025 --> Nov 2025 | Trial primary completion date: Feb 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    1year
    Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp (clinicaltrials.gov)
    P3, N=165, Recruiting, Biofrontera Bioscience GmbH | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    Ameluz (aminolevulinic acid)
    over1year
    Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) (clinicaltrials.gov)
    P2, N=20, Recruiting, The Center for Clinical and Cosmetic Research
    New P2 trial
    |
    Ameluz (aminolevulinic acid)
    over1year
    Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Case Comprehensive Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Ameluz (aminolevulinic acid)
    over1year
    Duration of Ameluz Application in Acral Actinic Keratoses Response (clinicaltrials.gov)
    P4, N=28, Terminated, Royal Cornwall Hospitals Trust | Dr Xie abroad on other research, current PI Dr John Frewen not at main centre, no other available PI identified. Study suspended.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    over1year
    Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp (clinicaltrials.gov)
    P3, N=165, Recruiting, Biofrontera Bioscience GmbH | Trial completion date: Apr 2025 --> Mar 2026 | Trial primary completion date: Jul 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    almost2years
    Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). (clinicaltrials.gov)
    P3, N=186, Active, not recruiting, Biofrontera Bioscience GmbH | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date
    |
    Ameluz (aminolevulinic acid)
    almost2years
    Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults (clinicaltrials.gov)
    P2, N=126, Recruiting, Biofrontera Bioscience GmbH | Trial completion date: Mar 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    Ameluz (aminolevulinic acid)